Arcutis Raises Sales Outlook as ZORYVE Grows 45%
Specialty dermatology companies should note that rising marketing and sales spend is accompanying this topical drug's revenue gains.
Updated on Nov. 4, 2026 in Corporate Finance
Westlake Village-based Arcutis Biotherapeutics reported third quarter 2026 results, with ZORYVE net product revenue of $143.9 million, and raised its full-year 2026 net product sales guidance to $535 million-$545 million. For specialty dermatology companies and their commercial teams, the update signals continued unit demand for a topical prescription product.
Why it matters
The year-over-year revenue increase was predominantly driven by higher unit demand and modest improvements in gross-to-net deductions, while SG&A rose to $99.6 million on greater marketing spend and expanded sales personnel. That mix shows how a commercial-stage specialty drug company is reinvesting revenue growth into promotion and headcount rather than holding margins flat.
ZORYVE generated $143.9 million in Q3 2026 net product revenue, up 45% year over year and 11% sequentially, with Q3 SG&A of $99.6 million and R&D of $22.4 million. Cash and marketable securities stood at $259.8 million as of September 30, 2026, against a raised full-year net product sales guidance of $535 million-$545 million.
The players
Arcutis Biotherapeutics
A Westlake Village, California specialty pharmaceutical company that commercializes topical prescription dermatology treatments, led by its ZORYVE franchise, and is approved in the United States and Canada.
U.S. Food and Drug Administration
The federal agency that reviews and approves prescription drug applications and sets action dates that determine when dermatology products can be marketed.
The details
Revenue growth came mainly from more prescriptions filled, with only modest gains in gross-to-net deductions, meaning the rebates and discounts paid to payers and channel partners shrank slightly as a share of sales. Operating expenses rose on two fronts: marketing for the Skin to Believe In awareness campaign, and additional sales personnel. R&D rose on ARQ-234 clinical development costs and medical affairs investment.
Timeline
September 30, 2026: third quarter ended.
October 2026: Rob Scott appointed to the Board of Directors.
November 4, 2026: financial results announced and Rob Lisicki named chief commercial officer.
February 23, 2027: FDA target action date for the ZORYVE cream 0.05% infant indication.
Q1 2027: expected FDA decision on the infant indication and hidradenitis suppurativa results.
Market Landscape
Arcutis is advancing ZORYVE from its established atopic dermatitis and psoriasis footprint toward younger patients and new indications such as vitiligo and hidradenitis suppurativa. The pattern of expanding one approved topical molecule across adjacent dermatology conditions is a common path for specialty companies seeking durable revenue.
Operators in specialty pharmacy, dermatology practice management, and medical marketing should watch how promotional spending and sales headcount expansion affect cost structures in this segment. Companies planning their own revenue forecasts can use this quarter's guidance raise as a reference point for how demand and gross-to-net trends are being reported.
The takeaway
Growth in this quarter came mostly from volume rather than pricing concessions, a pattern operators in similar categories can test against their own unit and deduction data. Calendar the February 23, 2027 FDA action date and review the Q1 2027 results when they arrive.
What happens next
The FDA's target action date of February 23, 2027 for the ZORYVE cream 0.05% infant indication is the next scheduled decision point, with hidradenitis suppurativa results also expected in Q1 2027.
Further reading
For context on how companies translate revenue growth into guidance and spending decisions, explore Corporate Finance coverage.
